| 5.7 0.19 (3.45%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.59 | 1-year : | 10.27 |
| Resists | First : | 7.35 | Second : | 8.8 |
| Pivot price | 5.79  |
|||
| Supports | First : | 5.01 | Second : | 4.17 |
| MAs | MA(5) : | 5.56 |
MA(20) : | 6.3 |
| MA(100) : | 5.16 |
MA(250) : | 3.4 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 22.5 |
D(3) : | 19 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 12.46 | Low : | 1.29 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NERV ] has closed above bottom band by 43.9%. Bollinger Bands are 7.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.77 - 5.8 | 5.8 - 5.83 |
| Low: | 5.44 - 5.47 | 5.47 - 5.5 |
| Close: | 5.65 - 5.7 | 5.7 - 5.74 |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Fri, 10 Apr 2026
Minerva Neurosciences (NASDAQ: NERV) proxy: charter amendments, say‑on‑pay vote - Stock Titan
Tue, 07 Apr 2026
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - The Globe and Mail
Mon, 06 Apr 2026
Minerva Neurosciences (NASDAQ: NERV) sets 2026 meeting and proposal deadlines - Stock Titan
Wed, 01 Apr 2026
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan
Tue, 31 Mar 2026
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia - Seeking Alpha
Wed, 25 Mar 2026
Schizophrenia drug combo showed no safety issues as Phase 3 starts - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 68.1 (%) |
| Shares Short | 560 (K) |
| Shares Short P.Month | 433 (K) |
| EPS | -34.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.14 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | -1.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|